Stocks › BCRX

BIOCRYST PHARMACEUTICALS INC

BCRX·Nasdaq·United States United States·USD
$7.22
-0.10 (-1.37%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BCRX
BIOCRYST PHARMACEUTICALS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BCRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of BCRX by members of U.S. Congress · 5 on record · 2 in the last 12 months
All congressional trades →
PoliticianStockTypeFiledTraded
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA BCRXBIOCRYST PHARMACEUTICALS INC · Stock Purchase
$1,001 - $15,000
Sep 4, 2026 Jul 10, 2026 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA BCRXBIOCRYST PHARMACEUTICALS INC · Stock Purchase
$1,001 - $15,000
Dec 15, 2025 Nov 13, 2025 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BCRXBIOCRYST PHARMACEUTICALS INC · Stock Purchase
$1,001 - $15,000
Nov 11, 2023 Oct 16, 2023 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BCRXBIOCRYST PHARMACEUTICALS INC · Stock Sale
$1,001 - $15,000
Oct 15, 2023 Sep 15, 2023 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BCRXBIOCRYST PHARMACEUTICALS INC · Stock Purchase
$1,001 - $15,000
Sep 16, 2022 Aug 11, 2022 Filing ↗

Whale Activity

Position changes in BCRX reported for 2026-09-30 by 367 institutional filers
Increased: 97New: 51Held: 50Decreased: 122Closed: 33No prior filing: 14
  • Increased97
  • New51
  • Held50
  • Decreased122
  • Closed33
  • No prior filing14
FilerSharesValueChange
BlackRock, Inc.24.3M$202.7Mincreased
DEERFIELD MANAGEMENT COMPANY, L.P.15.5M$129.0Mincreased
STATE STREET CORP12.3M$102.4Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC11.3M$93.9Mdecreased
TCG Crossover Management, LLC11.0M$91.8Mheld
VANGUARD PORTFOLIO MANAGEMENT LLC10.5M$87.7Mdecreased
PERCEPTIVE ADVISORS LLC10.3M$85.8Mdecreased
Janus Henderson Group Ltd.10.3M$85.3M—
TWO SIGMA INVESTMENTS, LP7.2M$60.0Mincreased
Jones Hill Capital LP7.1M$59.0Mnew
Aberdeen Group plc6.5M$53.9Mincreased
GEODE CAPITAL MANAGEMENT, LLC6.1M$50.4Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by BCRX insiders, by quarter · Form 4
-250.0K-125.0K0125.0K250.0K2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: -70.0K2025 Q32025 Q4: -214.3K2025 Q42026 Q1: -199.9K2026 Q12026 Q2: -73.7K2026 Q22026 Q3: 02026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

1,044 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Stonehouse Jon PDirector Grant / award +644 $9.70 $6K Aug 31, 2026 Form 4 ↗
Milne Jill C.Director Grant / award +1,288 $9.70 $12K Aug 31, 2026 Form 4 ↗
MILANO VINCENTDirector Grant / award +1,159 $9.70 $11K Aug 31, 2026 Form 4 ↗
McKee Amy EDirector Grant / award +644 $9.70 $6K Aug 31, 2026 Form 4 ↗
Frank StevenDirector Grant / award +1,288 $9.70 $12K Aug 31, 2026 Form 4 ↗
Milne Jill C.Director Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
Galson Steven KDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
LEVIN ALAN GDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
Frank StevenDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
SANDERS MACHELLEDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
MILANO VINCENTDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
Stonehouse Jon PDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
McKee Amy EDirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
HEGGIE THERESADirector Grant / award +15.3K $0.00 $0 Jun 11, 2026 Form 4 ↗
Milne Jill C.Director Grant / award +1,262 $8.91 $11K May 29, 2026 Form 4 ↗
Stonehouse Jon PDirector Grant / award +631 $8.91 $6K May 29, 2026 Form 4 ↗
McKee Amy EDirector Grant / award +631 $8.91 $6K May 29, 2026 Form 4 ↗
MILANO VINCENTDirector Grant / award +1,122 $8.91 $10K May 29, 2026 Form 4 ↗
Frank StevenDirector Grant / award +1,262 $8.91 $11K May 29, 2026 Form 4 ↗
McKee Amy EDirector Sale −11.2K $8.97 $100K May 18, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding BCRX · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
9.6M$95.8M0.89%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
8.1M$80.7M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
6.0M$60.5M0.07%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
2.9M$29.1M0.02%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.8M$28.4M0.03%Jun 30, 2026
abrdn Healthcare Investors2.3M$23.2M1.71%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
2.5M$22.8M0.07%Jul 31, 2026
VANGUARD STRATEGIC EQUITY FUND
VANGUARD HORIZON FUNDS
2.3M$22.6M0.19%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
2.1M$21.5M0.14%Jun 30, 2026
abrdn Healthcare Opportunities Fund2.1M$20.9M2.53%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list BCRX's shares (CUSIP 09058V103), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    Nov 16, 2026 · ↗
  • Rajeev ShahSCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    Nov 16, 2026 · ↗
  • Peter KolchinskySCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    Nov 16, 2026 · ↗
  • RA Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
    Nov 16, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 12.3M shares4.8%
    Nov 10, 2026 · ↗
  • RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
    Aug 14, 2026 · ↗
  • Rajeev ShahSCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
    Aug 14, 2026 · ↗
  • Peter KolchinskySCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
    Aug 14, 2026 · ↗
  • RA Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
    Aug 14, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 15.2M shares6.0%
    Aug 7, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming biocryst pharmaceuticals as client

No lobbying filings found naming BIOCRYST PHARMACEUTICALS INC as the client.

  • BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q3$10K
    Filing ↗
  • BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q2$20K
    Filing ↗
  • BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q1 · MED, DIS$20K
    Filing ↗
  • BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2017 Q4 · DIS, MED$20K
    Filing ↗
  • BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2017 Q3 · MED, DIS$20K
    Filing ↗

Government Contracts

Federal awards to biocryst pharmaceuticals · USAspending
$182KAwarded · 2 contracts on record
  • Department of Veterans AffairsEMERGENCY ORLADEYO$30K
    May 21, 2026 · ↗
  • Department of Veterans AffairsORLADEYO 150MG CAP$151K
    May 19, 2026 · ↗

U.S. Patents

Recent USPTO applications naming BIOCRYST PHARMACEUTICALS INC

No USPTO patent applications found for BIOCRYST PHARMACEUTICALS INC.

Annual Financials

From BCRX's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income$341.0M-$2.5M-$103.7M-$148.4M-$177.7M
Net income$263.9M-$88.9M-$226.5M-$247.1M-$184.1M
Diluted EPS$1.21-$0.43-$1.18-$1.33-$1.03
Operating cash flow$347.4M-$52.0M-$95.1M-$161.8M-$142.2M
Cash and equivalents$89.7M$104.7M$110.6M$304.8M$504.4M
Total assets$514.2M$490.4M$517.0M$550.0M$588.2M
Total liabilities$633.3M$966.4M$972.5Mn/an/a
Shareholders' equity-$119.2M-$475.9M-$455.5M-$294.6M-$107.0M

As BIOCRYST PHARMACEUTICALS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in BCRX's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 5, 2026
    EDGAR ↗
  • 8-K/A · Items 2.05Exit or disposal costsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 2.05, 7.01, 9.01Exit or disposal costs · Reg FD disclosureJun 29, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 12, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 6, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 9.01Reg FD disclosureMay 4, 2026
    EDGAR ↗

About BIOCRYST PHARMACEUTICALS INC

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDURHAM, NC
IncorporatedDE